梯瓦制药 TEVA 深沪

已收盘 12-19 16:00:00 美东时间

30.345

+0.030

+0.10%

华盛通

立即下载

最高30.56
今开30.14
成交量 815.52万股
最低 24.78
昨收 30.315
总市值 336.83亿
52周最高 30.56
市盈率 ^静 80.55
换手率 0.73%
52周最低 12.465
委比 22.82%
总股本 11.10亿
历史最高 69.8535
量比 1.12
振幅 19.07%
历史最低 6.07
每手 1
风险率 3.58%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report

Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.

11-20 00:26
Teva Pharmaceutical Industries Unveils Teva Rise Innovation Platform

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive technologies including AI, industry 4.0 smart

11-19 21:08
投资者提问：请问公司与美国梯瓦制药战略合作发展进展如何？是否已经盈利模式？

投资者提问：请问公司与美国梯瓦制药战略合作发展进展如何？是否已经盈利模式？董秘回答(复星医药SH600196)：投资者您好！截至目前，公司与美国梯瓦就...

11-14 17:41
多款知名进口药告别国内市场

界面新闻记者 | 黄华界面新闻编辑 | 谢欣 10月15日晚，国家药监局公众号显示，注销费卡华瑞的氯雷他定片（10mg，国药准字H20040557）等80个...

10-20 09:25
【华安证券·医疗器械】先健科技（01302）：结构心+外周介入领军企业，国际化业务加速

（来源：华安证券研究）结构心+外周介入领军企业，有望合作多个外延BD项目公司是结构心+外周介入高值耗材领域的领军企业，公司目前主营业务呈现“3+N”业...

08-06 08:00
$1350亿交易总额惊呆了！国产1类新药惊喜连连，恒瑞、石药、三生亮眼，创新出海热度高涨

精彩内容随着系列政策的大力推动，叠加国内创新同质化严重的背景下，越来越多中国创新药企业纷纷踏上“创新转型、扬帆出海”的新赛道。据不完全统计，2024年至今达成...

07-31 17:33
梯瓦制药(TEVA)盘前涨3.14% 第二财季扭亏为盈

金吾财讯 | 梯瓦制药(TEVA)盘前涨3.14%，报17.06美元。消息面上，公司公布第二季度业绩，利润为2.82亿美元，而去年同期亏损8.46亿美元。经调整每股收益为0.66美元，超出市场预期的0.63美元。期内营收42亿美元，与去年同期相比基本持平，但略低于市场预期的42.8亿美元。公司将其2025年关键创新产品的收入展望中值上调了9500万美元，同时维持全年168亿-172亿美元的整体收入指引。同时公司提高了经调整每股收益指引的下限至2.50-2.65美元。公司的转型计划有望到2027年实现约7亿美元的净节省，预计2025年将实现约7000万美元。公司仍专注于到2027年实现30...

07-30 20:41
苹果、微软、亚马逊、Meta财报来袭

作者丨Oliver Rodzianko 编译 | 华尔街大事件本周科技巨头、能源巨头、金融公司、医疗保健行业领袖和消费者品牌将陆续发布大量财报。焦点将集中...

07-28 20:40
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

The final analysis of the PEARL study presented at EAN 2025 Congress in Helsinki demonstrated that fremanezumab provided sustained effectiveness in reducing migraine attacks over two years with favorable safety and high adherence rates, benefiting both chronic and episodic migraine patients.

06-23 07:00
复星医药战略新布局！抗PD1-IL2疗法引领肿瘤治疗新突破

（转自：摩熵医药大数据） 6月16日，复星医药与Teva Pharmaceutical Industries（“梯瓦”，TEVA）共同宣布，双方通过各自的子公...

06-19 09:59

派息除权日	每股总股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-21	0.04	1991-09-19
1991-05-20	0.04	1991-07-20
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-17	0.04	1990-09-17
1989-05-22	0.04	1989-06-19
1988-12-06	0.04	1988-12-30
1988-09-08	0.04	1988-10-05
1988-06-10	0.03	1988-07-20
1988-04-12	0.03	1988-05-16
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-09	0.04	1987-08-05
1987-06-22	0.03	1987-07-14
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名称	梯瓦制药
行业分类	制药
业务描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦制药 TEVA 深 沪

30.345

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

梯瓦制药 TEVA 深沪